Posted by Michael Wonder on 21 Nov 2019
Drug for ultra rare disease comes with ultra high price tag
21 November 2019 - Givlaari’s net price will be $442,000 after discounts included.
Alnylam Pharmaceuticals’ Givlaari became the first drug to win U.S. approval for patients with an ultra-rare and devastating metabolic disorder. Shares jumped on the news.
It will come with an annual wholesale price tag of $575,000. Patients will need to take it for life.
